The FDA approved the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel, making it the second such treatment for blood cancers in the United States. The therapy is indicated for adults with certain non-Hodgkin lymphomas who have tried at least two other treatments.

中文翻译：

---

FDA批准第二种CAR T细胞疗法

FDA批准了嵌合抗原受体T细胞疗法axicabtagene ciloleucel，使其成为美国第二种用于血液癌的治疗方法。该疗法适用于患有某些非霍奇金淋巴瘤且已尝试了至少两种其他治疗方法的成年人。